Coloplast's urology business takes growth leap after Covid-19 dive

Two years after Coloplast considered selling off its urology division, President and CFO at the company Anders Lonning-Skovgaard is happy they decided to keep and invest in the area, though the grounds for comparison this year were favorable.
Photo: Niels Hougaard/ERH
Photo: Niels Hougaard/ERH

While Coloplast's business area Continence Care saw an organic growth of 5 percent in the financial year that just ended, where the Ostomy Care also grew with 6 percent, the medtech company's urology division skyrocketed with an organic growth of 19 percent in the same period, the company's states in its 2020/2021 financial full-year report. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading